Table 1.

Incidence of GABHS infections in treated group and control group with RPTIs before enrollment and in the next 12 months

	Monthly GABHS frequency on enrollment	Monthly GABHS in the next 12 months	Wilcoxon signed-rank test
SsK12 group	0.38±0.08	0.03±0.07	Significant at P<0.001
Control group	0.39±0.08	0.17±0.1	Significant at P<0.001
Wilcoxon signed-rank test	Not significant	Significant at P<0.001

Abbreviations: GABHS, group A beta-hemolytic streptococci; RPTIs, recurrent pharyngo-tonsillar infections; SsK12, Streptococcus salivarius K12.